Investigation of tolerability and quality of life for carboplatin-based chemotherapy in an elderly urothelial carcinoma patient undergoing hemodialysis: a case report

Table 1 The measured AUC of carboplatin and hematologic toxic effects for 3 cycles of chemotherapy

Cycle	Doses of anticancer agents (mg)		Measured AUC of CBDCA (mg/mL min)	Neutrophil count (/μL)		Platelet count (×10³/μL)		Hemoglobin (g/dL)
Cycle	CBDCA	GEM	Measured AUC of CBDCA (mg/mL min)	Pretreatment	Nadir	Pretreatment	Nadir	Pretreatment	Nadir
First	160	1160	5.96	2100	315	168	40	11.0	8.2
Second	135	1160	4.97	5733	1248	285	60	11.0	9.5
Third	135	1160	–	4095	800	258	129	9.5	8.5

CBDCA carboplatin, GEM gemcitabine, AUC area under the concentration-time curve

ISSN: 2055-0294